Newsbenzinga
This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval
· Published
Article summary
Novartis wins traditional FDA approval for Fabhalta, a first-in-class oral treatment slowing kidney decline in adult IgAN.
An excerpt from the original article.
Comments —
Loading comments…